Ramlan Nasution Suwandi Sugandi Aaron Tigor Sihombing Anglita Yantisetiasti Betthy S Hernowo


Objective: To evaluate the role of prostate basal cell staining in diagnosing Gleason score 6 prostate cancer. Materials & Methods: During research period, we collected 20 medical records and paraffin block specimens of Gleason score 6 prostatic adenocarcinoma patients. Specimens were taken from prostate needle biopsy. Demographic data and PSA level were extracted from medical records. Basal cells were detected by immunohistochemical staining for antikeratin 34β-E12 on paraffin block specimens analyzed by an experienced pathologist. Positive results suggest a benign lesion. Results: Mean age is 70 ± 6,5 years. Mean prostate volume and PSA level was 52±17cc and 25±21 ng/ml. Three specimens (15%) showed presence of basal cells on antikeratin 34β-E12 staining, which indicated benign lesions. Leucocyturia was found in all patients of this group. There was a significant association between PSA level and antikeratin 34β-E12 staining (p=0,03). In multivariate analysis, there is no significant association between antikeratin 34β-E12 staining with age, prostate volume, and leucocyturia. Conclusions: 15 % cases of prostatic cancer Gleason score 6 still showed basal cell existence. Immunohistochemical staining of basal cell should be considered in suspicious cases of prostatic cancer. 



Gleason score 6 prostate cancer, basal cell, antikeratin 34β-E12


Hedrick L, Epstein J. Use of keratin 903 as an adjunct in diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13 (5): 389-96.

Shin M, Fujita MQ, Yasunaga Y, Okuyuma A, Aozasa K. Utility of immunohistochemical detection of high molecular weight cytokeratin for differential diagnosis of proliferative conditions of the prostate.

Acimovic M, Govedararevic V, Mitrovic D. Correlation of high-molecular cytokeratin in tissue of prostatic cancer with Gleason score and PSA. Acta Chir Iugosl 2005; 52 (4): 45-9.

Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34βE12+p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003; 27 (3): 365-71.

Kozuka Y, Imai H, Yamanaka M, Kozuka M, Uchida K, Shiraishi T. Histopathological features of prostate cancer. Nippon Rinsho 2005; 63 (2): 231-6.

Kumar, Abas, Fausto, Mitchell. The male genital system. In: Vogelstein B, Kinzler KW, editors. Basic Pathology. 8th ed. New York: Elsevier; 2008. p. 675-700.

Kirk JW, Epstein J. The utility of basal cell-spesific anti-cytokeratin antibody in diagnosis of prostate cancer. Am J Surg Pathol 1995; 19 (3): 251-60.

Oliai BR, Kahane H, Epstein J. Can basal cells be seen in adenocarcinoma of prostate. An immunohistochemical study using high molecular cytokeratin (clone 34βE12) antibody. Am J Surg Pathol 2002; 26 (9): 1151-60.

Gregor M. Clinical pathology of urologic tumors. India: Replika Press; 2007. p. 98-99.

Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: Review literature. Histopathology 2005; 47 (1): 1-16.

Hameed O, Humphrey PA. Immunochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005; 22 (1): 88-104.

Helpap B. Prostatic adenocarcinoma-still a diagnostic problem. Verh Dtsch Ges Pathol 2004; 88: 152-7.

Zhou M, Magi-Galluzi C, Epstein J. Prostate basal cell lessions can be negative for basal cell keratins: A diagnostic pitfall. Anal Quant Cytol Histol 2006; 28 (3): 125-9.

January 2010 Vol. 17 No. 1
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University